4-cyano-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboryl)benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-cyano-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboryl)benzoate
• 英文别名: methyl 4-cyano-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate；4-cyano-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzoic acid methyl ester；methyl 4-cyano-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboryl)benzoate
• 化学式: C₁₅H₁₈BNO₄
• 分子量: 287.123
• InChiKey: OIRKTPQIGRCKNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.64
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  68.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-cyano-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboryl)benzoate 在 盐酸 、 sodium periodate 作用下， 以 四氢呋喃 、 水 为溶剂， 以64%的产率得到(2-cyano-5-(methoxycarbonyl)phenyl)boronic acid
  参考文献：
  名称：

  快速紧密的硼酸盐形成，实现点击生物正交共轭

  摘要：

  新的点击生物正交反应系统设计成使快速连接（ķ ON ≈340 米-1 小号-1）一个刚性的环状二醇（nopoldiol）和仔细优化硼酸伙伴的缀合衍生物，2-甲基-5-羧甲基苯基硼酸。使用NMR和荧光光谱研究，发现对应于硼酸酯在水中低微摩尔浓度分钟内可逆地形成，从而提供亚微摩尔的平衡常数（ķ当量≈10 5 -10 6 米-1）。用模型蛋白硫氧还蛋白和白蛋白证明了在生理条件下的有效蛋白结合，并通过质谱和凝胶电泳进行了表征。

  DOI：

  10.1002/anie.201510321
• 作为产物：
  描述：

  对氰基苯甲酸甲酯 、 联硼酸频那醇酯 在 catalyst: (Ir(OMe)(COD))2/4,4'-(tBu)2-2,2'-bipy 作用下， 以 四氢呋喃 为溶剂， 以65%的产率得到4-cyano-3-(4,4,5,5-tetramethyl-1,3,2-dioxaboryl)benzoate
  参考文献：
  名称：

  芳族C-H键的空间定向官能化：芳烃和杂环中邻位到氰基的选择性硼酰化

  摘要：

  描述了 4-取代苄腈的 Ir 催化硼化。与亲电芳香取代和定向邻位金属化相反，当 4-取代基大于氰基时，CH 活化/硼酸化能够在与氰基相邻的 2-位进行官能化。当使用过量的硼烷试剂时，在某些情况下可以通过形成单一区域异构体来实现二硼化。还报道了空间定向硼酸化扩展到氰基取代的五元和六元环杂环。

  DOI：

  10.1021/ja0428309

文献信息

• [EN] IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET LEUR UTILISATION COMME MODULATEURS DES KINASES DÉPENDANTES DES CYCLINES
  申请人：NOVARTIS AG

  公开号：WO2010125402A1

  公开（公告）日：2010-11-04

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+-O- or CR3; Y is N, N+-O- or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  该发明提供了式(I)的化合物及其盐、互变异构体、溶剂合物和N-氧化物；其中Q为CH或N；X为N、N+-O-或CR3；Y为N、N+-O-或CR3a；R1和R2分别选自氢和各种定义中的取代基；或R1和R2与它们连接的原子一起，形成一个可选择地取代的含氢碳环或杂环芳香或非芳香环，成员数为4到7；R3选自氢和各种取代基；R3a选自氢和各种定义中的取代基。还提供了含有式(I)的化合物的药物组合物，制备该化合物的方法以及该化合物的医药用途。式(I)的化合物具有作为CDK激酶抑制剂的活性，并可用于治疗癌症等增殖性疾病。
• Sterically Directed Functionalization of Aromatic C−H Bonds:  Selective Borylation Ortho to Cyano Groups in Arenes and Heterocycles
  作者：Ghayoor A. Chotana、Michael A. Rak、Milton R. Smith

  DOI：10.1021/ja0428309

  日期：2005.8.1

  Ir-catalyzed borylations of 4-substituted benzonitriles are described. In contrast to electrophilic aromatic substitutions and directed ortho metalations, C-H activation/borylation enables functionalization at the 2-position, adjacent to the cyano group, when the 4-subsitutent is larger than cyano. When an excess of borane reagent is used, diborylation can be achieved with a single regioisomer being

  描述了 4-取代苄腈的 Ir 催化硼化。与亲电芳香取代和定向邻位金属化相反，当 4-取代基大于氰基时，CH 活化/硼酸化能够在与氰基相邻的 2-位进行官能化。当使用过量的硼烷试剂时，在某些情况下可以通过形成单一区域异构体来实现二硼化。还报道了空间定向硼酸化扩展到氰基取代的五元和六元环杂环。
• IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES
  申请人：Howard Steven

  公开号：US20120101064A1

  公开（公告）日：2012-04-26

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N + —O − or CR 3 ; Y is N, N + —O − or CR 3a ; R 1 and R 2 are independently selected from hydrogen and various substituents as defined in the claims; or R 1 and R 2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R 3 is selected from hydrogen and various substituents; and R 3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  本发明提供了式（I）的化合物及其盐，互变异构体，溶剂合物和N-氧化物；其中Q为CH或N；X为N，N+—O−或CR3；Y为N，N+—O−或CR3a；R1和R2分别选自氢和定义在权利要求中的各种取代基；或者R1和R2与它们附着的原子一起连接形成一个可选取代的4到7个成员的碳环芳香族或杂环芳香族或非芳香族环；R3选自氢和各种取代基；而R3a选自氢和定义在权利要求中的各种取代基。还提供了含有式（I）化合物的药物组合物，制备化合物的过程以及化合物的医药用途。式（I）化合物具有作为CDK激酶抑制剂的活性，并可用于治疗增殖性疾病，如癌症等。
• Imidazole derivatives and their use as modulators of cyclin dependent kinases
  申请人：Howard Steven

  公开号：US08598217B2

  公开（公告）日：2013-12-03

  The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O− or CR3; Y is N, N+—O− or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.

  本发明提供了公式（I）的化合物及其盐、互变异构体、溶剂合物和N-氧化物；其中Q为CH或N；X为N、N+—O−或CR3；Y为N、N+—O−或CR3a；R1和R2独立地选择氢和各种取代基，如权利要求中所定义的；或者R1和R2与它们所连接的原子一起，链接形成一个选择性取代的4到7个成员的碳环或杂环芳香或非芳香环；R3选择氢和各种取代基；R3a选择氢和各种取代基，如权利要求中所定义的。还提供了含有公式（I）化合物的制药组合物、制备化合物的方法以及化合物的医药用途。公式（I）化合物具有作为CDK激酶抑制剂的活性，并且在治疗增殖性疾病，如癌症等方面是有用的。
• Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors
  作者：Young Shin Cho、Hayley Angove、Christopher Brain、Christine Hiu-Tung Chen、Hong Cheng、Robert Cheng、Rajiv Chopra、Kristy Chung、Miles Congreve、Claudio Dagostin、Deborah J. Davis、Ruth Feltell、John Giraldes、Steven D. Hiscock、Sunkyu Kim、Steven Kovats、Bharat Lagu、Kim Lewry、Alice Loo、Yipin Lu、Michael Luzzio、Wiesia Maniara、Rachel McMenamin、Paul N. Mortenson、Rajdeep Benning、Marc O'Reilly、David C. Rees、Junqing Shen、Troy Smith、Yaping Wang、Glyn Williams、Alison J.-A. Woolford、Wojciech Wrona、Mei Xu、Fan Yang、Steven Howard

  DOI：10.1021/ml200241a

  日期：2012.6.14

  Herein, we describe the discovery of potent and highly selective inhibitors of both CDK4 and CDK6 via structure-guided optimization of a fragment-based screening hit. CDK6 X-ray crystallography and pharmacokinetic data steered efforts in identifying compound 6, which showed >1000-fold selectivity for CDK4 over CDKs 1 and 2 in an enzymatic assay. Furthermore, 6 demonstrated in vivo inhibition of pRb-phosphorylation and oral efficacy in a Jeko-1 mouse xenograft model.